GlassScriptPhysician profile
Nicholas John Agresti
NPI 1669634010
$9,873.76
in general payments reported to CMS, 2019-2025
32 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $299 · 2021: $551 · 2022: $1,743 · 2023: $1,738 · 2024: $2,444 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,531.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,914.64 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Madrigal Pharmaceuticals | $904.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $791.94 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $646.81 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $588.11 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $556.40 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $490.34 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $431.37 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $377.85 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $283.24 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $245.31 | 2021-2025 | |
| Pfizer INC. | $194.04 | 2019-2025 | |
| Lilly USA, LLC | $179.80 | 2024-2025 | Omvoh |
| Histosonics, INC. | $148.97 | 2024 | |
| Intercept Pharmaceuticals, INC. | $144.68 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $139.74 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $111.13 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $102.54 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $100.80 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $95.09 | 2019-2025 | Rebyota |
| Redhill Biopharma INC. | $84.48 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $65.06 | 2020 | |
| Vivus LLC | $58.21 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $56.25 | 2023-2024 | Givlaari |
| Olympus America INC. | $33.03 | 2019-2024 | Evis X1 Video System Center |
| Ipsen Biopharmaceuticals, INC | $23.25 | 2025 | Iqirvo |
| Novo Nordisk INC | $22.03 | 2025 | Wegovy |
| Abbott Laboratories | $21.70 | 2019 | |
| Enterra Medical, INC. | $21.51 | 2025 | |
| Allergan, INC. | $14.45 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.02 | 2020 | |
| Boston Scientific Corporation | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Agresti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.